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This is a monocyte-derived human macrophage, stained in blue with a protein of lipid metabolism called lipin-1, 
which localizes on the surface of these huge cytoplasmic formations that tend to distribute in the periphery of 
the cells (Slide 2 – untitled) [1]. These formations are lipid droplets and, as you can see, macrophages have 
many of them. If we take a closer look at one of these lipid droplets, what we see is something like this (Slide 3 
– Lipid Droplets):  a phospholipid monolayer decorated with a variety of proteins and inside a hydrophobic core 
composed of triglycerides (TAG) and cholesteryl esters (CE). For many years these lipid droplets were thought 
of only as storage organelles for neutral lipids to be mobilized in the case of energy needs. Today we know that, 
in addition to that storage role, lipid droplets serve a wide variety of roles in cell physiology. For the purposes of 
this talk I will only highlight two of them. In the first place, lipid droplets may serve as signaling platforms for 
signaling enzymes to dock and interact; this is particularly true for lipid signaling enzymes; cytosolic 
phospholipase A2α (cPLA2α), cyclooxygenase-2 or lipin-1, all localize to this organelle. I will get back to 
cPLA2α in a little while; this is the first enzyme in the eicosanoid cascasade, the one that opens the door to 
eicosanoid production by releasing free arachidonic acid (AA) from phpospholipids [2,3]. In second place, lipid 
droplets have been found to play key roles in the development and progression of inflammatory metabolic 
disorders, of which the most common is cardiovascular disease (Slide 4 – Initiation of Atherosclerosis).  
Atherosclerosis is major cause for cardiovascular disease, and diabetes accelerates it [2]. Atherosclerosis is 
initiated by the abnormal activation of endothelial cells, which is produced e.g. by increased lipid in the blood 
(dyslipidemia) or sugar in blood (diabetes). Endothelial cells release a wide variety of products with 
inflammatory potential that may attract monocytes and favor the interaction of these monocytes with the 
endothelial cells, which results in the infiltration of the activated monocytes into the vessel wall. There, the 
monocyte will differentiate into macrophage and will take up enormous amounts of lipids that have deposited 
into that space (primarily cholesterol esters), store them into lipid droplets thus becoming foam cells, and 
establishing an atheroma plaque. These macrophages keep releasing proinflammatory mediators, thus 
perpetuating damage. With time, smooth muscle cells from the tunica media will proliferate and reach the 
macrophage-rich area thus making things worse.  
Among the many compounds secreted by endothelial cells that is, or has been the focus of our interest for so 
many years now: arachidonic acid (AA). Endothelial cells secrete relatively large amounts of this fatty acid 
(pathophysiological range up to 10 µM). Thus we took our human monocytes and exposed them to 10 µM AA, 
as I just said, the pathophysiological concentration (Slide 5 – AA Induces Lipid Droplet Formation) [4]. Middle 
columns show the monocytes stained with DAPI to visualize their nuclei, and on the right column,  you can see 
that monocytes exposed to this fatty acid produced lots of lipid droplets, stained in green with BODIPY. So 
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these data provide an interesting concept, which is that  the monocytes are bound to become a foam cell, and are 
starting to become one even before crossing the endothelial layer, and even before to becoming an actual 
macrophage. This adds an interesting twist to the diagram shown in the previous slide, I believe. We also 
studied the effect of palmitic acid, a fatty acid that at much higher concentrations is proinflammatory [5]. 
However at 10 µM it did not induce any lipid droplet formation, thus suggesting that the AA effect is somewhat 
specific. Mass measurements confirmed that the AA-treated cells indeed produce elevated amounts of both 
TAG and CE (Slide 6 – AA Induces Neutral Lipid Formation) [4]. Of course, AA is a lipid (Slide 7 – AA 
Effects on Lipid Droplet Formation), so this elevated neutral lipid production could just occur as a consequence 
of a ‘passive’ incorporation of the fatty acid into neutral lipids. A second possibility is that AA actually activates 
the cells and thus neutral lipid production is the consequence of an ‘active’ signaling component which 
promotes the incorporation of other fatty acids in addition to AA. To distinguish between the two possibilities 
we used triacsin C, a compound that inhibits some members of the acyl-CoA synthetase family of enzymes and 
that, at least in monocytes, blocks the incorporation of the exogenous AA into neutral lipids (the ‘passive’ 
component)  but not the incorporation of the endogenous fatty acids (the ‘active’ component). We took the 
monocytes and treated them with AA in the absence or presence of triacsin C (Slide 8 – TAG Fatty Acid 
Composition in Lipid Droplets) [4]. If you look on the left hand side, triacsin C blocked partially the production 
of TAG suggesting that the effect of AA works through both passive and active components. Now if you look 
on the right, this is the fatty acid profile of TAG, from left to right, myristic, palmitic, palmitoleic, stearic, oleic, 
linoleic and arachidonic acids. In the absence of triacsin C there is a huge incorporation of AA, however in the 
presence of the inhibitor this is totally prevented. Thus the inhibitor worked pretty nicely, but the important 
thing here is that no other fatty acid was affected by triacsin C; incorporation is the same whether or not triacsin 
C is present. So this highlights the active signaling component induced by AA and, because this is the 
phenomenon we are interested in and wish to characterize, from now on all the experiments include triacsin C. 
This slide shows the fatty acid profile of TAG and CE esters in the presence of triacsin C (Slide 9 – Fatty Acid 
Content of TAG and CE) [4]. The data on the left are the same as those in the previous slide. The profiles are 
very similar in qualitative terms in both cases, and of course there is no AA because of the presence of triacsin 
C. The important thing in this slide is the fatty acid in the purple box: palmitoleic acid. You can see there is very 
little in resting cells, and that it hugely increases in activated cells, hence we suspect if must bear some 
biological significance. For those in the audience who work in atherosclerosis, diabetes, obesity, or lipid 
metabolism in general, you all know that palmitoleic acid is one of the “rising stars” of the field; it has been 
implicated in regulating inflammation, and it has been suggested as well that this fatty acid functions as an 
adipokine, released by the adipose tissue to regulate lipid metabolism in liver. Thus our work adds to these 
results, and shows that activated monocytes synthesize palmitoleic acid and store it in significant quantities in 
the neutral lipids of lipid droplets.  
I will get back to palmitoleic acid in a moment, but now please allow me to open a short parenthesis to discuss 
some data on the mechanism through which AA induces lipid droplets in the monocytes. In this experiment we 
measured lipid droplet formation by flow cytometry (Slide 10 – Role of cPLA2α in Lipid Droplet Formation). 
Thus the cells were treated or not with AA and treated afterward with BODIPY to stain the lipid droplets and, 
fluorescence was measured by flow cytometry. This shift to the right of the fluorescence of  AA treated cells 
indicates that they have made lipid droplets. However, if we knock-down cPLA2α by siRNA this fluorescence 
shift is not observed, indicating no lipid droplet formation. Thus, cPLA2α is essential for the monocytes to make 
lipid droplets in the response to AA, which is an interesting conclusion because cPLA2α is precisely the enzyme 
that mediates AA release from endogenous sources after receptor stimulation. Here, the situation is the other 
way around, exogenous AA activates cPLA2α to produce lipid droplets. cPLA2α is known to be phosphorylated 
in cells by members of the MAPK family and this phosphorylation actvates the enzyme. Thus, we measured the 
effect of AA on MAP kinases and found that AA activates p38, JNK, but not the ERKs (Slide 11 – AA 
Activates p38 and JNK) [4]. In accordance with these data, AA induces the phosphorylation of cPLA2α (Slide 
12 – AA Stimulates cPLA2α Phosphorylation by both p38 and JNK) [4]. This phosphorylation is not affected by 
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inhibitors of ERK, as aexpected since AA does not activate the ERKs. However, when both inhibitors are 
present, cPLA2α phosphorylation is reduced at levels even lower than those found in unstimulated cells. Now, 
how does this relate with lipid droplet formation? (Slide 13 – Role of cPLA2α in LD Formation) [4]. Here we 
have our monocytes with their nuclei stained in blue with DAPI. When treated with AA they make lipid droplets 
in green (BODIPY) and, in agreement with previous slides, if  we block cPLA2α, in this case with a pretty well 
established inhibitor, pyrrophenone [6,7], lipid droplet formation is strongly inhibited, as expected. Now if we 
use the p38 inhibitor not very much happens, the cells still prodce significant numbers of lipid droplets (Slide 14 
– Role of cPLA2α in LD Formation) [4]. The same occurs if we use the JNK inhibitor. However, if we use both 
at the same time, strong inhibition of lipid droplet formation is observed. Thus the same conditions that block 
cPLA2α phosphorylation/activation lead to inhibition of lipid droplet formation. As a summary of this data, we 
show this model (Slide 15 – Simultaneous Activation of p38 and JNK by AA Activates cPLA2α), where AA 
activates p38 and JNK (but not ERK) and this two kinases act on cPLA2α to activate it, so that the enzyme 
regulates lipid droplet synthesis. Two points to consider. First is that it is possible that p38 and JNK act both on 
cPLA2α simultenously to activate it; however, since both kinases phosphorylate cPLA2α on the same residue, 
this sems a bit odd, We hipothesize that maybe there is an intermediate kinase that is activated by both p38 and 
JNK, and this kinase is the one that directly phosphorylates cPLA2α. We are currently working in the lab to 
verify whether this hipothesis is correct. Second, how is cPLA2α mediating lipid droplet formation? The answer 
is: we do not know. We know however that cPLA2α does not regulate the synthesis of neutral lipids, so we 
speculate that some step of the formation, the budding of the lipid droplet out of the endoplasmic reticulum may 
be controlled by cPLA2α.  
Well with this we close the parenthesis and come back to plamitoleic acid again. We were here in this slide 
(Slide 16 – Fatty Acid Content of TAG and CE; repeat of slide 9). The next question that we want to answer is, 
what is the origin of ths palmitoleic plus other fatty acids? (Slide 17 – Origin of the Fatty Acids – Possibilities). 
There are two possibilities: first is that the fatty acids come from membrane phospholipids. If this is the case, 
then total cellular fatty acid should remain constant. The second possibility is that A activated de novo fatty acid 
synthesis. In this case, total cellular fatty acid should increase. Thus we measured total fatty acids in cells and 
the result is clear, there is an increase in cellular fatty acids, thus indicating that AA indeed activates fatty acid 
de novo synthesis to make lipid droplets (Slide 18 – Total Fatty Acid Content of Human Monocytes) [4]. On the 
right we have the fatty acid profile of whole cells, that is neutral lipids plus phospholipids, and still under these 
conditions a significant increase in palmitoleic acid levels is observed.  
Four genes control fatty acid synthesis in mammalian cells (Slide 19 – Expression of Genes Involved in de novo 
Fatty Acid Synthesis). These are acetyl-CoA carboxylase, that makes malonyl-CoA. Malonyl-CoA is used by 
fatty acid synthase to make palmitic acid, which can be either elongated to stearic or desaturated to palmitoleic 
acid. Stearc acid can be desaturated to oleic acid by the same desaturase that makes palmitoleic acid. We 
measured these four genes by qPCR and found that all of them were increased by AA in monocytes (Slide 20 – 
Expression of Genes Involved in de novo Fatty Acid Synthesis). As a conclusion of this part of my talk (Slide 
21 – Lipid Inflammatory Signals Regulate Cellular Lipid Metabolism), we believe that our data constitute an 
excellent example of a lipid proinflammatory signal, AA, acting on its target cell, the monocyte, to deregulate 
lipid metabolism, in this case increasing fatty acid synthesis. Among other things, this has the effect of 
increasing the cellular amount of palmitoleic acid, which can be sent to lipid droplets or exert other effects on 
the cells. I said before that palmitoleic acid was proinflammatory, so it could be sad that, in a way, AA is 
perpetuating itself, or better the proinflammatory signal, with a different face. Outside is AA, inside the cell is 
palmitoleic acid. 
For you to see actual data indicating that palmitoleic has proinflammatory properties, what this slide shows is an 
experiment where normal monocytes or monocytes loaded with palmitoleic acid are exposed to bacterial 
lipopolysaccharide, and the expression of various proinflammatory genes is measured (Slide 22 – Palmitoleic 
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Acid (16:1) as a Proinflammatory Lipid). We used lipopolysaccharide here just to obtain a very strong response 
[8]. It is clear that the cells enriched in palmitoleic acid produced more proinflammatory cytokines after 
stimulation. Now, in this experiment palmitoleic is not floating around as a free fatty acid; it has been taken by 
the cells and incorporated into various cellular lipid classes. So, whatever the mechanism for this increased 
production of cytokines is, the palmitoleic active molecule should be a lipid ester and, because the 
overwhelming majority of the palmitoleic acid is in phospholipids, we speculate that this bioactive entity is a 
phospholipid that contains palmitoleic acid. So we set out to determine the nature of this phospholipid. By using 
GC/MS we determined first the distribution of palmitoleic acid between phospholipid classes, 
phosphatidylinositol, phosphatidylethanolamine, phosphatidylcholine, and phosphatidylserine in resting and 
AA-treated monocytes (Slide 23 – 16:1-Contaning Phospholipid Classes (GC/MS)). In resting cells the richest 
class in 16:1 is phosphatidylcholine, but this changes in the activated cells. In qualitative terms, the class that 
increases the most is phosphatidylinositol. There is little in resting but a clear increase is seen in actvated cells. 
This fact, along with a technical reason that I will mention later, made us focus on this class of phospholipids. 
By using LC/MS [9-12] we separated the molecular species of phosphatidylinositol (Slide 24 – Novel 16:1-PI 
Species That Appear  After Activation (LC/MS)). To restrict the search and obtain only a few hits, we focused 
only on those palmitoleic phospholipids that showed up in activated cells but did not occur in resting cells. By 
doing this, we got two, maybe three species. The first one contains not one but two palmitoleyl lateral chains. 
The second one, which increased way more than the first one after activation, contains palmitoyl and 
palmitoleyl chains. Finally, there is maybe a third one, which contains stearic in addition to palmitoleic. 
Problem with this one is that it is isobaric with this other which is a major one. Isobaric means that they both 
have the same mass to charge ratio, thus we cannot resolve them with our machine. Thus at this point we cannot 
tell how much of this increase, if any, is actually due to the palmitoleic-containing lipid. Never mind, we still 
have two excellent candidates for our studies. So our strategy from now on is to make these lipids in the lab, to 
introduce them into the cells, and see what happens. Well, for doing this it is really fortunate that these lipids are 
of the inositol class, because inositol lipids are anionic, and anionic lipids can be transfected into cells just like 
you transfect DNA or RNA [13]. This is the technical reason I was referring to before. Thus, by  using 
lipofectamine, lipofectin, or anything on that sort, you name it, you can get the lipid inside the cells and study its 
effects on a number of cell functions (Slide 25 – Intracellular Delivery of Anionic Phospholipids). At this point I 
have to stop the palmitoleic acid story here because we still have no data to show but, please let me talk instead 
for the rest of my talk about an unusual phospholipid, also a PI molecule, which does not contain palmitoleic 
acid, but two arachidonoyl tails (Slide 26 – 1,2-Diarachidonoyl-sn-glycero-3-phosphoinositol), because we 
believe this lipid may be involved in the regulation of innate immune responses in macrophages [11]. This 
experiments were conducted in murine macrophages so feom now to the end of the talk I will refer to these 
cells. 
In this slide there is the full profile of AA-containing phospholipids of murine macrophages (Slide 27 – AA-
Containing Phospholipids in Resting Macrophages) [11]. In red there are the choline phospholipids, in green the 
etanolamine phospholipids, in yellow the inositol lipids, and in pink the serine phospholipids. By class on the 
right, the richest class is the green, followed by the red. Lesser amounts in yellow and pink. Well what happens 
when we stimulate the cells? Of course AA will be liberated and the amount of these species will decrease. This 
iswhat we have in this slide (Slide 28 – AA-Containing Phospholipids in Zymosan-Stimulated Macrophages) 
[11]. Most of the red phospholipids decrease significantly, as it does one of the yellow ones. The pink vary little 
and the green do not change at all. But this is well described so no point here. The points is, you see two lipids 
that actually increase, not decrease. The first one, red, is PC(20:4/20:4), but again this is no new, as this 
phospholipid was described some 25 years ago. However a second one, the inositol equivalent, PI(20:4/20:4) 
also increases and we believe this is really new stuff [9, 11, 14]. So we proceeded to characterize it. This lipid 
increases linearly with time after zymosan stimulation and tends to stay elevated, a behavior that is compatible 
with it playing a role (Slide 29 – Stimulated Production of  PI(20:4/20:4) in Macrophages) [11]. To verify that 
this lipid is a pathophysiological consequence we soght for it in a simple animal model of inflammation, mouse 
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peritonits (Slide 30 – Production of PI(20:4/20:4) in Mouse Peritonitis) [10]. In this model, we inject zymosan 
in the peritoneum and this will result in the efflux of phagocytic cells, primarily neutrophils Thus we collect 
cells from the peritoneum at different times and measure PI(20:4/20:4), which yo can see clearly increases. In 
the opposite, this other species, PI(18:0/20:4), a major one, decreases. So this lipidcould be pathophysiologically 
important so we decided to fin its funcion in cells. We prepared the lipid in the lab and introduced it in cells 
using the strategy I described previously (Slide 31 – Incorporation of PI(20:4/20:4) Into Cells). We made the 
complexes, gave them to the cells, waited, stimulated with zymosan and looked for responses. Initially we 
focused on gene expression, because that is the most “fashionable” response one can measure, right? So we 
stimulated the cells, either untreated or loaded with PI(20:4/20:4) and measured the expression of various genes 
by qPCR (Slide 32 – PI(20:4/20:4) Does Not Regulate Gene Expression) [11]. Zymosan induced significant 
increases which were the same in control and in PI(20:4/20:4)-loaded cells. Also, the lipid did not do anything 
on its own. So it is clear that PI(20:4/20:4) does not regulate gene expression, which was quite a disappointing 
finding. However it got us thinking that perhaps we would have better to look at short-term, acute responses. 
And among these, what a better response to measure than production of reactive oxygen intermediates, 
superoxide anion in this case? (Slide 33 – PI(20:4/20:4) Regulates Superoxide Anion Production) [11]. We 
stimulated the macrophages with either PMA or zymosan and obtained nice responses, which were significantly 
increased when PI(20:4/20:4)-loaded cells were used. Granted, the increases are not very impressive; however, 
when we used cells loaded with an irrelevant lipid, no increase was appreciated. More importantly, when we 
assayed another immediate response, that is, secretion of lysosomal hydrolases lysozyme, we observed again a 
significantly increased response when PI(20:4/20:4)-loaded cells were used (Slide 34 – PI(20:4/20:4) Regulates 
Lysozyme Release). 
So, as a conclusion of my talk, and this is my last slide (Slide 35 – Novel Lipid Mediators of Macrophage 
Activation), we have described novel lipid mediators of phagocyte activation, palmitoleic acid and 
PI(20:4/20:4). The fun starts now in the lab, as we have to define pathways and effectors impacted upon by 
these mediators. Just to conclude, I would like to thank all the people in my lab who have been involved in these 
projects, and to my collaborators, Dr. M. Balboa from my institute, and  Dr. E. Claro from Barcelona, and also 
to our sponsors, thanks to whom our lipidomics work can continue without interruptions ((Slide 36 – 
Acknowledgments). And I thank you very much for your attention.   
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